Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Auxilium Pharmaceuticals (Nasdaq: AUXL) fell more than 13% in early trading after the company revealed lower demand for procedures relating to the hand disorder known as Dupuytren's contracture.

So what: Interestingly, "lower demand" doesn't equal lower revenue. Sales of its signature treatment, XIAFLEX, rose 130% year over year to $13.1 million, with $10.3 million of that originating in the United States.

Now what: Auxilium also reported a sharply better profit picture. Net loss narrowed to $0.08 per share, down from $0.27 a year ago. Analysts expected a $0.21 loss, according to data compiled by Yahoo! Finance. Do you think today's selling was overdone? Would you buy shares of Auxilium Pharmaceuticals at current prices? Please weigh in using the comments box below.

Interested in more information about Auxilium Pharmaceuticals? Add it to your watchlist.

Fool contributor Tim Beyers is a member of the Motley Fool Rule Breakers stock-picking team. He didn't own shares in any of the companies mentioned at the time of publication. Check out Tim's portfolio holdings and Foolish writings, or connect with him on Google+ or Twitter, where he goes by @milehighfool. You can also get his insights delivered directly to your RSS reader.

Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.